ESC 2020 | 2020 Atrial Fibrillation Guidelines: News on Diagnosis, Classification, and Care

New guidelines for the diagnosis and treatment of atrial fibrillation (AF) were released at the 2020 European Society of Cardiology (ESC) virtual congress. This document incorporates several findings from the latest clinical trials, but also represents a great shift in terms of how physicians from different specialties should classify and manage arrhythmia after confirming the diagnosis.

ESC 2020 | Guías de Fibrilación Auricular 2020: Novedades sobre diagnóstico, clasificación y tratamiento

The new guidelines emphasize that, in order to start treatment, you first need to document the arrhythmia. In that sense, the recommendations promote the use of ECG to that end.

That may seem obvious to cardiologists, but patients often complain about palpitations or compatible symptoms before other specialists, who underestimate such symptom. In the best of cases, they conduct an ECG on the spot, when the patient may have reverted spontaneously to sinus rhythm.

New guidelines emphasize active and constant search.

After confirming the diagnosis of atrial fibrillation, the next step is its characterization. The standard practice used temporal patterns, such as ‘paroxysmal’ (persistent or permanent), but this classification has many limitations.


Read also: ESC 2020 | Post PCI Trimetazidine: No Adverse Events or Great Benefits.


The new guidelines propose a new classification dubbed “4S-AF.” This refers to 4 items: stroke risk, symptom severity, severity of A-fib burden, and substrate severity.

Stroke risk can be estimated using the CHA2DS2-VASc.

Symptom severity can be assessed using the EHRA score or other similar tools.


Read also: ESC 2020 | Against the Grain, ASA Monotherapy Appears Superior after TAVR.


Severity of A-fib burden can be ascertained using duration time, spontaneous reversion to sinus rhythm, etc.

Finally, substrate severity can be estimated through age, comorbidities, atrial enlargement, and fibrosis.

Scores and supplementary studies may change over time, but the 4S-AF strategy will remain.

guias-ESC-FA

Original Title: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS).

Reference: Hindricks G et al. European Heart Journal (2020) 00, 1125.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...

The Two Sides of the Coin: What Do CHAMPION-AF and CLOSURE-AF Teach Us About Left Atrial Appendage Closure?

Letter to the editor: Juan Manuel Pérez Asorey Percutaneous left atrial appendage closure (LAAO) is currently going through one of the most interesting stages of...

CLOSURE-AF: Percutaneous Left Atrial Appendage Closure versus Medical Therapy in Atrial Fibrillation

Percutaneous left atrial appendage closure has been proposed as an alternative to anticoagulation in patients with atrial fibrillation and high bleeding risk; however, comparative...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

High Ischaemic Risk Criteria in Chronic Coronary Syndrome: Prevalence and Prognosis

Despite advances in the management of chronic coronary syndrome (CCS), including the widespread use of drug-eluting stents (DES) and the optimization of medical therapy,...

Management of Valve Thrombosis in TAVI: Current Evidence-Based Approach

The expansion of transcatheter aortic valve implantation (TAVI) into younger and lower-risk populations has brought bioprosthetic valve thrombosis to the forefront as a clinically...

Experience with the intra-annular self-expanding Navitor valve: data from the STS/ACC TVT registry

The expansion of TAVI, with the introduction of new-generation devices, has prioritized not only periprocedural safety, but also the preservation of coronary access, more...